Contributions
Abstract: PB1472
Type: Publication Only
Session title: Bone marrow failure syndromes incl. PNH - Clinical
Background
Hematopoietic stimulation therapy is one of the most important dimensions for the treatment of aplastic anemia. The recovery of platelets is the plight of AA recovery.
Aims
To analyze the total effect of rhTPO and(or) rhIL-11 combined with immunosuppressive therapy (IST) for AA patients and compare the effects between them.
Methods
we enrolled 131 AA patients who were divided into 4 groups: the IST group (36 cases), the rhIL-11+IST group (14 cases), the rhTPO+IST group (42 cases), and the rhIL-11+rhTPO+IST group(39 cases).Survival time as well as bone marrow hematopoiesis, peripheral blood cells, immune cell subsets of patients in each group at the 3, 6, and 9 months after ATG/ALG treatment were collected and analyzed.
Results
Patients who were applied IST coupled with rhTPO (including rhTPO+IST group and rhIL-11+rhTPO+IST group) performed much better than without rhTPO group in terms of ORR, improvement of bone marrow hematopoietic, megakaryocyte recovery and overall survival (OS). rhTPO collaborated by rhIL-11 could influence mDC number and help humoral immune reconstitution. Among all the parameters, bone marrow cellularity at 3 months is the only multivariate that affects OS.
Conclusion
rhTPO is a powerful supplement to IST in treatment of AA, patients could benefit from several aspects, including elevating ORR, shortening bone marrow hematopoietic and magekarocyte recovery time, helping humoral immune reconstitution, and prolonging OS. IL-11 and TPO have a synergistic effect on the mechanism, the combination of these drugs may be the “icing on the cake” for IST treatment of AA.
Keyword(s): Aplastic anemia
Abstract: PB1472
Type: Publication Only
Session title: Bone marrow failure syndromes incl. PNH - Clinical
Background
Hematopoietic stimulation therapy is one of the most important dimensions for the treatment of aplastic anemia. The recovery of platelets is the plight of AA recovery.
Aims
To analyze the total effect of rhTPO and(or) rhIL-11 combined with immunosuppressive therapy (IST) for AA patients and compare the effects between them.
Methods
we enrolled 131 AA patients who were divided into 4 groups: the IST group (36 cases), the rhIL-11+IST group (14 cases), the rhTPO+IST group (42 cases), and the rhIL-11+rhTPO+IST group(39 cases).Survival time as well as bone marrow hematopoiesis, peripheral blood cells, immune cell subsets of patients in each group at the 3, 6, and 9 months after ATG/ALG treatment were collected and analyzed.
Results
Patients who were applied IST coupled with rhTPO (including rhTPO+IST group and rhIL-11+rhTPO+IST group) performed much better than without rhTPO group in terms of ORR, improvement of bone marrow hematopoietic, megakaryocyte recovery and overall survival (OS). rhTPO collaborated by rhIL-11 could influence mDC number and help humoral immune reconstitution. Among all the parameters, bone marrow cellularity at 3 months is the only multivariate that affects OS.
Conclusion
rhTPO is a powerful supplement to IST in treatment of AA, patients could benefit from several aspects, including elevating ORR, shortening bone marrow hematopoietic and magekarocyte recovery time, helping humoral immune reconstitution, and prolonging OS. IL-11 and TPO have a synergistic effect on the mechanism, the combination of these drugs may be the “icing on the cake” for IST treatment of AA.
Keyword(s): Aplastic anemia